upfront therapy for the asct-eligible patient: (pt. 3 of 5 - imf ash satellite)
Published 4 years ago • 240 plays • Length 36:29Download video MP4
Download video MP3
Similar videos
-
23:47
evolution of upfront therapy for the asct-ineligible patient (pt 2 of 5 - imf ash 2019 satellite)
-
13:14
2020 treatment algorithm for multiple myeloma and conclusions (part 5 of 5 - imf ash 2019 satellite)
-
13:02
upfront asct versus kcd consolidation with k maintenance in transplant-eligible, newly diagnosed mm
-
28:51
diagnosis and risk stratification of plasma cell disorders (pt 1 of 5 - imf ash satellite)
-
3:51
should i have an autologous stem cell transplant (asct)?
-
53:40
the current therapeutic landscape for relapsed or refractory mm (pt 4 of 5 - imf ash 2019 satellite)
-
57:52
first-line or frontline therapy options in multiple myeloma | 2023 imf patient and family seminar
-
3:47
what are the immediate and long-term side effects of an autologous stem cell transplant (asct)?
-
2:47:42
accelerating toward curing myeloma: new data, new agents, and evolving treatment paradigm
-
2:59
real world tandem asct for high risk mm
-
47:45
best therapies for myeloma patients opting for transplant
-
2:00:59
imf patient & family webinar: multiple myeloma - new treatments, diversity, and caregiver support
-
9:39
frontline therapy: imwg conference series ash 2019
-
5:05
myeloma university | overview of autologous stem cell transplant for treatment of multiple myeloma
-
1:53
transplantation for consolidation in multiple myeloma
-
18:32
updates in multiple myeloma from asco 2020
-
3:14
what are the frontline myeloma treatment options?
-
17:54
proposed 2019 treatment algorithms for mm
-
31:50
newly diagnosed and relapsed myeloma